Differential involvement of guanylate cyclase and potassium channels in nitric oxide-induced hyporesponsiveness to phenylephrine in endotoxemic rats

被引:38
作者
da Silva-Santos, JE [1 ]
Terluk, MR [1 ]
Assreuy, J [1 ]
机构
[1] Univ Fed Santa Catarina, Dept Pharmacol, BR-88015420 Florianopolis, SC, Brazil
来源
SHOCK | 2002年 / 17卷 / 01期
关键词
aorta; blood pressure; lipopolysaccharide; septic shock; vasoplegia;
D O I
10.1097/00024382-200201000-00012
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
This study evaluated the involvement of nitric oxide (NO), guanylate cyclase, and potassium channels in the long-lasting vascular hyporesponsiveness to phenylephrine induced by Escherichia coli lipopolysaccharide (LPS) in vitro and in vivo. Experiments in rat aorta rings with endothelium incubated with LPS (10 mug/mL) for 12 h showed that the hyporesponsiveness depends on guanylate cyclase activity and tetraethylammonium-sensitive, but not voltage- or ATP-dependent, potassium channels. Pressor responses to phenylephrine were reduced by 50% in rats injected 8 and 24 h before with LPS (10 mg/kg, intraperitoneally), Pretreatment with NO synthase inhibitors (NOS; N-omega-nitro-L-arginine methyl ester [L-NAME], 55 mu mol/kg or aminoguanidine, 244 mu mol/kg, intraperitoneally) fully prevented LPS-incluced hyporesponsiveness. When administered just before phenylephrine, L-NAME (11 mu mol/kg, intravenously) reversed the hyporesponsiveness in rats injected 8 h, but not in those injected 24 h before with LPS, whereas 1H-[1,2,4]-oxadiazolo-[4,3-a]-quinoxalin-1 (ODQ, 11 mu mol/kg, intravenously) reversed the hyporesponsiveness in animals injected 24 h, but not in those injected 8 h before with LPS. Tetraethylammonium (360 mu mol/kg, intravenously) reestablished normal responses to phenylephrine in rats injected 8 and 24 h before with LPS. Again, neither voltage- nor ATP-dependent potassium channels appears to be involved. Western blot showed that NOS expression peaked at 8 h, decreasing to low levels 24 h after LPS injection. Therefore, NO is important in initiating LPS-induced hyporesponsiveness to vasoconstrictors, but not in maintaining it for long periods. Once NO has exerted its effects and even when NOS expression is minimal, the long-lasting hyporesponsiveness appears to depend on a complex interplay between guanylate cyclase and potassium channel activation.
引用
收藏
页码:70 / 76
页数:7
相关论文
共 34 条
[1]
NITRIC-OXIDE AND CGMP CAUSE VASORELAXATION BY ACTIVATION OF A CHARYBDOTOXIN-SENSITIVE K-CHANNEL BY CGMP-DEPENDENT PROTEIN-KINASE [J].
ARCHER, SL ;
HUANG, JMC ;
HAMPL, V ;
NELSON, DP ;
SHULTZ, PJ ;
WEIR, EK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7583-7587
[2]
INTERLEUKIN-1 ACTIVATES SOLUBLE GUANYLATE-CYCLASE IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS THROUGH A NOVEL NITRIC OXIDE-INDEPENDENT PATHWAY [J].
BEASLEY, D ;
MCGUIGGIN, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (01) :71-80
[3]
NITRIC-OXIDE DIRECTLY ACTIVATES CALCIUM-DEPENDENT POTASSIUM CHANNELS IN VASCULAR SMOOTH-MUSCLE [J].
BOLOTINA, VM ;
NAJIBI, S ;
PALACINO, JJ ;
PAGANO, PJ ;
COHEN, RA .
NATURE, 1994, 368 (6474) :850-853
[4]
BRANDTZAEG P, 1996, CURR TOP MICROBIOL, P16
[5]
Inhibition of nitric oxide formation with L-canavanine attenuates endotoxin-induced vascular hyporeactivity in the rat [J].
Cai, M ;
Sakamoto, A ;
Ogawa, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 295 (2-3) :215-220
[6]
Abnormal activation of K+ channels in aortic smooth muscle of rats with endotoxic shock:: electrophysiological and functional evidence [J].
Chen, SJ ;
Wu, CC ;
Yang, SN ;
Lin, CI ;
Yen, MH .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (02) :213-222
[7]
Role of nitric oxide and K+-channels in vascular hyporeactivity induced by endotoxin [J].
Chen, SJ ;
Wu, CC ;
Yen, MH .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (06) :493-499
[8]
Duration of the hemodynamic effects of NG-nitro-L-arginine methyl ester in vivo [J].
Conner, EM ;
Aiko, S ;
Fernandez, M ;
Battarbee, HD ;
Gray, L ;
Grisham, MB .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2000, 4 (02) :85-93
[9]
CUNHA FQ, 1994, IMMUNOLOGY, V81, P211
[10]
DEKIMPE SJ, 1994, J PHARMACOL EXP THER, V268, P910